Antitumor effect of in situ cryoablation with systemic immunotherapy on murine renal cell tumor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, D.S. | - |
dc.contributor.author | Ko, Y.H. | - |
dc.contributor.author | Choi, H. | - |
dc.contributor.author | Kang, S.H. | - |
dc.contributor.author | Bae, J.H. | - |
dc.contributor.author | Park, H.S. | - |
dc.contributor.author | Moon, D.G. | - |
dc.contributor.author | Cheon, J. | - |
dc.contributor.author | Yoon, D.K. | - |
dc.date.accessioned | 2021-09-09T15:50:21Z | - |
dc.date.available | 2021-09-09T15:50:21Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0494-4747 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/125320 | - |
dc.description.abstract | Purpose: To investigate synergistic effect of local cryoablation with systemic immunotherapy, the tumor control ability and immunologic responses of combining these two modalities was compared with that of cryoablation, surgical excision, and immunotherapy only group in a tumor re-challenge model. Materials and Methods: Preliminary experiments were performed in two stages. The first stage consisted of 36 Balb/c mice with Renca bearing tumors imbedded in the right thigh, and was treated with interleukin-2 (IL-2) and interferon-alpha (IFN-α) to evaluate the efficacy of immunotherapy and to determine the adequate dosage. The second stage was performed on 10 mice, to evaluate histological changes and efficacy after cryoablation. The main experiment was performed on 48 mice, divided into 6 groups of control with tumor implantation, excision of tumor, excision combined with immunotherapy, cryoablation of tumor, cryoablation with immunotherapy and control without tumor. After treatment, tumor re-challenge was performed with Renca cell, then the growth pattern was evaluated with physical measurements, and immune response was investigated with fluorescent activated cell sorter and cytotoxicity assay. Results: Preliminary studies on immunologic efficacy revealed that IL-2 and IFN-α have a dose dependent inhibition of tumor growth. The main experiment evaluating the efficacy of combination treatment revealed that cryoablation with immunotherapy proved to be most effective in terms of tumor recurrence and tumor growth inhibition, yet the difference was not statistically significant from monotherapy with cryoablation. However, cytotoxicity was significantly increased cryoablation with immunotherapy compared with other groups. Conclusions: Cryoablation on tumor re-challenge mice model showed advantages with immunotherapy most prominently in cytotoxicity. | - |
dc.format.extent | 9 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.title | Antitumor effect of in situ cryoablation with systemic immunotherapy on murine renal cell tumor | - |
dc.type | Article | - |
dc.identifier.doi | 10.4111/kju.2008.49.11.965 | - |
dc.identifier.scopusid | 2-s2.0-57049156061 | - |
dc.identifier.bibliographicCitation | Korean Journal of Urology, v.49, no.11, pp 965 - 973 | - |
dc.citation.title | Korean Journal of Urology | - |
dc.citation.volume | 49 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 965 | - |
dc.citation.endPage | 973 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001291840 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | alpha interferon | - |
dc.subject.keywordPlus | interleukin 2 | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal model | - |
dc.subject.keywordPlus | animal tissue | - |
dc.subject.keywordPlus | antineoplastic activity | - |
dc.subject.keywordPlus | apoptosis | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cancer immunotherapy | - |
dc.subject.keywordPlus | cancer inhibition | - |
dc.subject.keywordPlus | cancer recurrence | - |
dc.subject.keywordPlus | cancer surgery | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | cryoablation | - |
dc.subject.keywordPlus | cytotoxicity test | - |
dc.subject.keywordPlus | drug dose comparison | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug megadose | - |
dc.subject.keywordPlus | fluorescence activated cell sorter | - |
dc.subject.keywordPlus | histology | - |
dc.subject.keywordPlus | immune response | - |
dc.subject.keywordPlus | intermethod comparison | - |
dc.subject.keywordPlus | kidney carcinoma | - |
dc.subject.keywordPlus | low drug dose | - |
dc.subject.keywordPlus | mouse | - |
dc.subject.keywordPlus | multimodality cancer therapy | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | systemic therapy | - |
dc.subject.keywordPlus | treatment response | - |
dc.subject.keywordPlus | tumor growth | - |
dc.subject.keywordPlus | tumor volume | - |
dc.subject.keywordAuthor | Cryoablation | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Renal cell carcinoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.